Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Ipsen
- 28 Aug 2017 Planned End Date changed from 1 Jun 2018 to 28 Nov 2017.
- 28 Aug 2017 Planned primary completion date changed from 1 Jun 2018 to 28 Nov 2017.
- 28 Aug 2017 Status changed from recruiting to active, no longer recruiting.